Autonomic Retulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction (ANTHEM-HFrEF)

About this Study

The purpose of this study is to see if a new investigational device called the VITARIA system is safe and effective in treating heart failure.

Sponsor Protocol ID:ANTHEM-HFrEF
IRB Number:2018-0176
Actively Enrolling
Early Phase 1
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria

  1. Age 18 or above
  2. Willing and capable of providing informed consent
  3. Capable of participating in all testing associated with this clinical investigation.

Exclusion Criteria

  1. Presence of any other disease with an estimated life expectancy of less than 12 months
  2. Severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
  3. Malignancy with current or anticipated surgical or other treatment, excluding basal cell carcinoma
  4. Known or suspected non-compliance with medical therapy
  5. Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
  6. Involvement in any concurrent clinical study with an investigational therapy

Categories Click category to view its trials.
Heart Health
Participating Locations
Grants Ferry - UMMC
Jackson Medical Mall - UMMC Clinics
Pavilion - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Theresa Hickey Hutson
Phone Number: 601-815-8702
Principal Investigator:Long, Robert C, M.D.
How to participate in our Clinical Trials